Arial fibrillation in patients with chronic lymphocytic leukemia (CLL)

Tait D. Shanafelt, Sameer A Parikh, Peter Noseworthy, Valentin Goede, Kari G. Chaffee, Jasmin Bahlo, Timothy G. Call, Susan M. Schwager, Wei D Ding, Barbara Eichhorst, Kirsten Fischer, Jose F. Leis, Asher A Chanan Khan, Michael Hallek, Susan L Slager, Neil Elliot Kay

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Although preliminary data suggests that ibrutinib may increase risk of atrial fibrillation (AF), the incidence of AF in a general cohort of chronic lymphocytic leukemia (CLL) patients is unknown. We evaluated the prevalence of AF at CLL diagnosis and incidence of AF during follow-up in 2444 patients with newly diagnosed CLL. A prior history of AF was present at CLL diagnosis in 148 (6.1%). Among the 2292 patients without history of AF, 139 (6.1%) developed incident AF during follow-up (incidence approximately 1%/year). Older age (p < .0001), male sex (p = .01), valvular heart disease (p = .001), and hypertension (p = .04) were associated with risk of incident AF on multivariate analysis. A predictive model for developing incident AF constructed from these factors stratified patients into 4 groups with 10-year rates of incident AF ranging from 4% to 33% (p < .0001). This information provides context for interpreting rates of AF in CLL patients treated with novel therapies.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalLeukemia and Lymphoma
DOIs
StateAccepted/In press - Nov 24 2016

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Atrial Fibrillation
Incidence
Heart Valve Diseases
Multivariate Analysis
Hypertension

Keywords

  • atrial fibrillation
  • Chronic lymphocytic leukemia
  • ibrutinib
  • risk factors

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Arial fibrillation in patients with chronic lymphocytic leukemia (CLL). / Shanafelt, Tait D.; Parikh, Sameer A; Noseworthy, Peter; Goede, Valentin; Chaffee, Kari G.; Bahlo, Jasmin; Call, Timothy G.; Schwager, Susan M.; Ding, Wei D; Eichhorst, Barbara; Fischer, Kirsten; Leis, Jose F.; Chanan Khan, Asher A; Hallek, Michael; Slager, Susan L; Kay, Neil Elliot.

In: Leukemia and Lymphoma, 24.11.2016, p. 1-10.

Research output: Contribution to journalArticle

Shanafelt, Tait D. ; Parikh, Sameer A ; Noseworthy, Peter ; Goede, Valentin ; Chaffee, Kari G. ; Bahlo, Jasmin ; Call, Timothy G. ; Schwager, Susan M. ; Ding, Wei D ; Eichhorst, Barbara ; Fischer, Kirsten ; Leis, Jose F. ; Chanan Khan, Asher A ; Hallek, Michael ; Slager, Susan L ; Kay, Neil Elliot. / Arial fibrillation in patients with chronic lymphocytic leukemia (CLL). In: Leukemia and Lymphoma. 2016 ; pp. 1-10.
@article{3e1da7d901f3425785659f0087ecba5e,
title = "Arial fibrillation in patients with chronic lymphocytic leukemia (CLL)",
abstract = "Although preliminary data suggests that ibrutinib may increase risk of atrial fibrillation (AF), the incidence of AF in a general cohort of chronic lymphocytic leukemia (CLL) patients is unknown. We evaluated the prevalence of AF at CLL diagnosis and incidence of AF during follow-up in 2444 patients with newly diagnosed CLL. A prior history of AF was present at CLL diagnosis in 148 (6.1{\%}). Among the 2292 patients without history of AF, 139 (6.1{\%}) developed incident AF during follow-up (incidence approximately 1{\%}/year). Older age (p < .0001), male sex (p = .01), valvular heart disease (p = .001), and hypertension (p = .04) were associated with risk of incident AF on multivariate analysis. A predictive model for developing incident AF constructed from these factors stratified patients into 4 groups with 10-year rates of incident AF ranging from 4{\%} to 33{\%} (p < .0001). This information provides context for interpreting rates of AF in CLL patients treated with novel therapies.",
keywords = "atrial fibrillation, Chronic lymphocytic leukemia, ibrutinib, risk factors",
author = "Shanafelt, {Tait D.} and Parikh, {Sameer A} and Peter Noseworthy and Valentin Goede and Chaffee, {Kari G.} and Jasmin Bahlo and Call, {Timothy G.} and Schwager, {Susan M.} and Ding, {Wei D} and Barbara Eichhorst and Kirsten Fischer and Leis, {Jose F.} and {Chanan Khan}, {Asher A} and Michael Hallek and Slager, {Susan L} and Kay, {Neil Elliot}",
year = "2016",
month = "11",
day = "24",
doi = "10.1080/10428194.2016.1257795",
language = "English (US)",
pages = "1--10",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Arial fibrillation in patients with chronic lymphocytic leukemia (CLL)

AU - Shanafelt, Tait D.

AU - Parikh, Sameer A

AU - Noseworthy, Peter

AU - Goede, Valentin

AU - Chaffee, Kari G.

AU - Bahlo, Jasmin

AU - Call, Timothy G.

AU - Schwager, Susan M.

AU - Ding, Wei D

AU - Eichhorst, Barbara

AU - Fischer, Kirsten

AU - Leis, Jose F.

AU - Chanan Khan, Asher A

AU - Hallek, Michael

AU - Slager, Susan L

AU - Kay, Neil Elliot

PY - 2016/11/24

Y1 - 2016/11/24

N2 - Although preliminary data suggests that ibrutinib may increase risk of atrial fibrillation (AF), the incidence of AF in a general cohort of chronic lymphocytic leukemia (CLL) patients is unknown. We evaluated the prevalence of AF at CLL diagnosis and incidence of AF during follow-up in 2444 patients with newly diagnosed CLL. A prior history of AF was present at CLL diagnosis in 148 (6.1%). Among the 2292 patients without history of AF, 139 (6.1%) developed incident AF during follow-up (incidence approximately 1%/year). Older age (p < .0001), male sex (p = .01), valvular heart disease (p = .001), and hypertension (p = .04) were associated with risk of incident AF on multivariate analysis. A predictive model for developing incident AF constructed from these factors stratified patients into 4 groups with 10-year rates of incident AF ranging from 4% to 33% (p < .0001). This information provides context for interpreting rates of AF in CLL patients treated with novel therapies.

AB - Although preliminary data suggests that ibrutinib may increase risk of atrial fibrillation (AF), the incidence of AF in a general cohort of chronic lymphocytic leukemia (CLL) patients is unknown. We evaluated the prevalence of AF at CLL diagnosis and incidence of AF during follow-up in 2444 patients with newly diagnosed CLL. A prior history of AF was present at CLL diagnosis in 148 (6.1%). Among the 2292 patients without history of AF, 139 (6.1%) developed incident AF during follow-up (incidence approximately 1%/year). Older age (p < .0001), male sex (p = .01), valvular heart disease (p = .001), and hypertension (p = .04) were associated with risk of incident AF on multivariate analysis. A predictive model for developing incident AF constructed from these factors stratified patients into 4 groups with 10-year rates of incident AF ranging from 4% to 33% (p < .0001). This information provides context for interpreting rates of AF in CLL patients treated with novel therapies.

KW - atrial fibrillation

KW - Chronic lymphocytic leukemia

KW - ibrutinib

KW - risk factors

UR - http://www.scopus.com/inward/record.url?scp=84997079264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997079264&partnerID=8YFLogxK

U2 - 10.1080/10428194.2016.1257795

DO - 10.1080/10428194.2016.1257795

M3 - Article

C2 - 27885886

AN - SCOPUS:84997079264

SP - 1

EP - 10

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -